RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operation and Financial
Condition
On February 27, 2017, Ritter Pharmaceuticals, Inc. (the Company),
issued a press release announcing the financial results for the
three-month period and full year ending December 31, 2016,
entitled Ritter Pharmaceuticals Reports Fourth Quarter and Full
Year 2016 Financial Results and Provides Business Update (the
Press Release). A copy of the Press Release is furnished as
Exhibit 99.1 hereto and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section 18 of the United State Securities Exchange
Act of 1934, as amended, or otherwise subject to the liability of
Section 18. Furthermore, the information shall not be deemed
incorporated by reference into any registration statement or any
other filing under the United States Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
references in such filings.
Item 9.01. Financial Statements and
Exhibits
(d) Exhibits
| Exhibit No. |
Description |
||
| 99.1 |
Press Release dated February 27, 2017, entitled Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update |
About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues. RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Recent Trading Information
RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) closed its last trading session down -0.09 at 2.80 with 114,371 shares trading hands.
